Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment ((VR-MCI))
Feasibility, Usability, and Acceptability of Virtual Reality-Based Cognitive and Physical Rehabilitation in Individuals With Mild Cognitive Impairment (VR-MCI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Seema S Aggarwal, PhD, APRN, AGNP-C
- Phone Number: (713) 500-9946
- Email: Seema.S.Aggarwal@uth.tmc.edu
Study Contact Backup
- Name: Tela Todd
- Phone Number: (713) 500-7039
- Email: Tela.Todd@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Tela Todd
- Phone Number: (713) 500-7039
- Email: Tela.Todd@uth.tmc.edu
-
Contact:
- Seema Aggarwal, PhD, APRN, AGNP-C
- Phone Number: (713) 500-9946
- Email: Seema.S.Aggarwal@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clinical diagnosis of MCI (MoCA 18-26) or self-reported subjective cognitive decline (SCD)
- Capacity to provide informed consent
- Able to provide own transportation to sessions
- Speaks and understands English
- Ambulatory
Exclusion Criteria:
- Uncontrolled seizures or epilepsy
- Severe psychiatric illness or active suicidality
- Inability to follow instructions or tolerate VR (severe motion sickness)
- Cognitive impairment as a result of a known cause (e.g., dementia, stroke, Traumatic Brain Injury (TBI), medications, etc.)
- Any condition that the research team determines would interfere with safe participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Virtual Reality (VR) sessions
|
Participants will complete 3 supervised virtual reality (VR) sessions per week for 6 weeks for a total of 18 sessions using either the Real System VR headset or the Oculus Quest 2 VR headset.
Each session will last approximately 60 minutes, with time allocated for setup and brief symptom checks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility as assessed by the recruitment rate
Time Frame: from baseline to end of intervention (6 weeks)
|
from baseline to end of intervention (6 weeks)
|
|
|
Feasibility as assessed by the retention rate
Time Frame: from baseline to end of intervention (6 weeks)
|
from baseline to end of intervention (6 weeks)
|
|
|
Feasibility as assessed by the session completion rate
Time Frame: from baseline to end of intervention (6 weeks)
|
from baseline to end of intervention (6 weeks)
|
|
|
Usability as assessed by the System Usability Scale (SUS)
Time Frame: Post-intervention only (Final visit at 6 weeks)
|
The System Usability Scale (SUS) is a validated 10-item questionnaire used to assess participants' perceived usability of the intervention.
each rated on a 5-point Likert scale from 1 = Strongly Disagree, 2 = Disagree 3 = Neutral ,4 = Agree, 5 = Strongly Agree.
Scores range from 0 to 100, with higher scores indicating greater usability.
|
Post-intervention only (Final visit at 6 weeks)
|
|
Acceptability / Presence as assessed by the Presence Questionnaire (PQ)
Time Frame: Post-intervention only (Final visit at 6 weeks)
|
This is a 29 item questionnaire, each is scored on a seven-point Likert-type scale with a score range form 29-203. Higher scores indicate a greater sense of presence or immersion in the virtual environment.
|
Post-intervention only (Final visit at 6 weeks)
|
|
Tolerability / Side Effects as assessed by the Simulator Sickness Questionnaire (SSQ)
Time Frame: Before + immediately After each VR session
|
This is a 16 item questionnaire and each is scored form 0(none) to 3(severe).
Scores are combined using weighted subscales to generate a total score, with higher scores indicating greater simulator sickness
|
Before + immediately After each VR session
|
|
Adherence / Engagement as assessed by the session attendance as entered in VR system logs
Time Frame: Post-intervention only (Final visit at 6 weeks)
|
Post-intervention only (Final visit at 6 weeks)
|
|
|
Adherence / Engagement as assessed by the time from start to end of VR session as entered in VR system logs
Time Frame: Post-intervention only (Final visit at 6 weeks)
|
Post-intervention only (Final visit at 6 weeks)
|
|
|
Adherence / Engagement as assessed by the number of repetitions of the activity as indicated by device metrics
Time Frame: Post-intervention only (Final visit at 6 weeks)
|
Post-intervention only (Final visit at 6 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Seema Aggarwal, PhD, APRN, AGNP-C, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-26-0038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.